GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Price-to-Owner-Earnings
中文

Can Fite Biofarma (Can Fite Biofarma) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 2012. Start your Free Trial

As of today (2024-04-23), Can Fite Biofarma's share price is $1.97. Can Fite Biofarma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Can Fite Biofarma's Price-to-Owner-Earnings or its related term are showing as below:


CANF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.26
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-23), Can Fite Biofarma's share price is $1.97. Can Fite Biofarma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.00. Therefore, Can Fite Biofarma's PE Ratio for today is At Loss.

As of today (2024-04-23), Can Fite Biofarma's share price is $1.97. Can Fite Biofarma's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.00. Therefore, Can Fite Biofarma's PE Ratio without NRI for today is At Loss.


Can Fite Biofarma Price-to-Owner-Earnings Historical Data

The historical data trend for Can Fite Biofarma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Can Fite Biofarma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Price-to-Owner-Earnings falls into.



Can Fite Biofarma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Can Fite Biofarma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.97/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Can Fite Biofarma  (AMEX:CANF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Can Fite Biofarma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines